Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: an RNA interference therapy (vutrisiran) lowered mortality and recurrent cardiovascular events across heart failure severities in transthyretin amyloidosis; a deep neural network achieved expert-level automated diagnosis on 583k pediatric ECGs; and a decade-long, 68,028-patient STS/TVT registry analysis showed expanding use and stable technical success of mitral transcatheter edge-to-edge repair across nondegenerative etiologies.
Summary
Three impactful cardiology studies stood out today: an RNA interference therapy (vutrisiran) lowered mortality and recurrent cardiovascular events across heart failure severities in transthyretin amyloidosis; a deep neural network achieved expert-level automated diagnosis on 583k pediatric ECGs; and a decade-long, 68,028-patient STS/TVT registry analysis showed expanding use and stable technical success of mitral transcatheter edge-to-edge repair across nondegenerative etiologies.
Research Themes
- RNA interference therapeutics in cardiomyopathy
- AI-enabled pediatric ECG diagnostics
- Structural heart interventions across diverse MR mechanisms
Selected Articles
1. Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy.
In this exploratory subgroup analysis of the HELIOS-B randomized trial (n=654), vutrisiran reduced all-cause mortality and recurrent cardiovascular events across NYHA I–III, NT-proBNP tertiles, and early disease stages, with the greatest benefit in earlier, less severe ATTR-CM. Effects were consistent in patients not on tafamidis.
Impact: This RCT-based subgroup analysis supports early and broad adoption of vutrisiran in ATTR-CM by demonstrating consistent benefit across severities, informing clinical decision-making and trial design for stage-specific therapy.
Clinical Implications: Consider initiating vutrisiran earlier in the disease course of ATTR-CM to maximize clinical benefit; patients across NYHA I–III may derive benefit, with the largest effect in earlier stages. This may influence sequencing with tafamidis and monitoring strategies (e.g., NT-proBNP).
Key Findings
- Across NYHA I/II/III, hazard ratios for the composite of ACM and recurrent CV events favored vutrisiran (e.g., HR 0.54 in NYHA I; 0.77 in NYHA II; 0.68 in NYHA III).
- Benefit was most pronounced in earlier disease (e.g., NAC stage 1 HR 0.49) and lower NT-proBNP tertiles (e.g., <1,368 ng/L HR 0.52).
- Similar benefits were observed in patients not receiving tafamidis at baseline, supporting monotherapy efficacy.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design with up to 36 months follow-up
- Predefined clinical subgroups with consistent directionality of effect across multiple severity metrics
Limitations
- Exploratory subgroup analysis with limited power in smaller strata; some confidence intervals cross unity
- Excluded NYHA IV and some very advanced cases (NYHA III with NAC stage 3), limiting generalizability to the sickest patients
Future Directions: Head-to-head and sequencing studies versus tafamidis; pragmatic trials targeting early-stage ATTR-CM; biomarker-guided therapy and real-world effectiveness in NYHA III–IV and NAC stage 3.
BACKGROUND: Vutrisiran reduced the risk of all-cause mortality (ACM) and recurrent cardiovascular (CV) events in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149). OBJECTIVES: This study sought to assess the effect of vutrisiran in HELIOS-B patients with different heart failure severities. METHODS: HELIOS-B randomized patients with ATTR-CM with NYHA functional class I-III (functional class IV or functional class III with National Amyloidosis Centre [NAC] stage 3 were excluded) 1:1 to vutrisiran 25 mg or placebo every 3 months for up to 36 months. This exploratory subgroup analysis assessed the primary composite endpoint of ACM and recurrent CV events, ACM, and additional functional and biomarker endpoints. RESULTS: Of 654 patients, 84 (13%), 508 (78%), and 62 (9%) were in NYHA functional class I, II, and III, respectively. Median baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) level was 1,920 ng/L. Lower risk of ACM and recurrent CV events was observed with vutrisiran vs placebo across baseline severity subgroups: respective HRs were 0.54 (95% CI: 0.27-1.10), 0.77 (95% CI: 0.57-1.03), and 0.68 (95% CI: 0.33-1.41) in NYHA functional classes I, II, and III, respectively; 0.52 (95% CI: 0.30-0.88), 0.61 (95% CI: 0.37-1.00), and 0.93 (95% CI: 0.64-1.35) in NT-proBNP tertiles <1,368 ng/L, ≥1,368 and <2,691 ng/L, and ≥2,691 ng/L; 0.49 (95% CI: 0.34-0.72) and 1.08 (95% CI: 0.74-1.56) in NAC stages 1 and 2/3, respectively; and 0.69 (95% CI: 0.45-1.07) and 0.74 (95% CI: 0.53-1.02) in Columbia early and intermediate/late stages, respectively. Similar effects were observed in the monotherapy population (patients not on tafamidis at baseline) and across the additional endpoints evaluated. CONCLUSIONS: Vutrisiran demonstrated evidence of benefit across the range of baseline disease severities in HELIOS-B, with the greatest benefit in earlier, less severe disease. (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy [HELIOS-B]; NCT04153149).
2. Expert-Level Automated Diagnosis of the Pediatric ECG Using a Deep Neural Network.
Using 583,134 pediatric ECGs from 201,620 patients, a CNN achieved expert-level performance, outperforming commercial software for any abnormality (AUROC 0.94), WPW (0.99), and prolonged QTc (0.96). Blinded re-adjudication favored AI classifications over original reads when discordant.
Impact: This establishes a scalable, validated AI approach for pediatric ECG triage and diagnosis, addressing global shortages of pediatric cardiology expertise and enabling equitable access.
Clinical Implications: AI-ECG can be deployed to screen and triage pediatric ECGs for abnormalities, WPW, and QT prolongation, potentially reducing diagnostic delays and variability. Integration with clinician oversight and prospective external validation will enable safe adoption.
Key Findings
- CNN outperformed commercial software across tasks: any abnormality (AUROC 0.94; AUPRC 0.96), WPW (AUROC 0.99; AUPRC 0.88), prolonged QTc (AUROC 0.96; AUPRC 0.63).
- Blinded expert readjudication agreed with AI more often than with the original cardiologist reads for discordant cases (P=0.001 for any abnormality).
- Massive dataset included diverse ages (median 11.7 years) and conditions (11% congenital heart disease), supporting generalizability.
Methodological Strengths
- Extremely large cohort with expert-annotated labels and internal train/test split
- Independent blinded readjudication to assess discordant cases and mitigate reference bias
Limitations
- Single-center, retrospective design without external prospective validation
- Potential label noise and spectrum bias inherent to clinical datasets; unclear performance in low-resource acquisition settings
Future Directions: Prospective, multi-center external validation; workflow integration studies (assisted reading, triage); regulatory evaluation and fairness assessment across demographics and device vendors.
BACKGROUND: Disparate access to expert pediatric cardiologist care and interpretation of electrocardiograms (ECGs) persists worldwide. Artificial intelligence-enhanced ECG (AI-ECG) has shown promise for automated diagnosis of ECGs in adults but has yet to be explored in the pediatric setting. OBJECTIVES: This study sought to determine whether an AI-ECG model can accurately perform automated diagnosis of pediatric ECGs. METHODS: This retrospective single-center cohort study included all patients with an ECG at Boston Children's Hospital read by an experienced pediatric cardiologist (≥5,000 reads) between 2000 and 2022. A convolutional neural network was trained (75% of patients) and internally tested (25% of patients) on ECGs to predict ECG diagnoses. The primary outcome was a composite of any ECG abnormality (ie, detecting normal vs abnormal ECG). Secondary outcomes include Wolff-Parkinson-White syndrome (WPW) and prolonged QTc. Model performance was assessed with area under the receiver-operating (AUROC) and precision recall (AUPRC) curves. RESULTS: The main cohort consisted of 201,620 patients (49% male; 11% with known congenital heart disease) and 583,134 ECGs (median age 11.7 years [Q1-Q3: 3.1-16.9 years]; 56% any ECG abnormality, 1.0% WPW, and 5.3% with prolonged QTc). The AI-ECG model outperformed the commercial software interpretations for detecting any abnormality (AUROC 0.94; AUPRC 0.96), WPW (AUROC 0.99; AUPRC 0.88), and prolonged QTc (AUROC 0.96; AUPRC 0.63). During readjudication of ECGs with AI-ECG/original cardiologist read discordance, blinded expert readers were more likely to agree with AI-ECG classification than the original reader to detect any abnormality (P = 0.001), WPW (P = 0.01), and prolonged QTc (P = 0.07). CONCLUSIONS: Our model provides expert-level automated diagnosis of the pediatric 12-lead ECG, which may improve access to care.
3. Temporal Changes in Procedural Success and Clinical Outcomes of MTEER by Mechanism of MR: Analysis of the STS/TVT Registry.
In 68,028 real-world MTEER cases from 2013–2023, use expanded markedly to nondegenerative MR (19%→43%), especially functional MR. Technical success odds were higher for all mechanisms except acute ischemic MR; one-device procedures increased without compromising success, and 1-year mortality was similar to degenerative MR.
Impact: This nationwide registry analysis informs patient selection and procedural strategy as MTEER expands to functional MR, supporting broader adoption without sacrificing technical success or 1-year survival.
Clinical Implications: MTEER can be considered across MR mechanisms (excluding acute ischemic MR) with high technical success; increasing use of single-device strategies may streamline procedures without harming outcomes. One-year mortality appears similar between functional and degenerative MR in practice.
Key Findings
- Nondegenerative MR cases increased from 19% to 43% of MTEER procedures over a decade, led by functional MR growth.
- Technical success odds exceeded those of degenerative MR for all mechanisms except acute ischemic MR.
- Single-device implantation increased (54.6% to 64.7%) without reducing technical success; 1-year mortality was similar between functional and degenerative MR.
Methodological Strengths
- Very large national registry spanning 10 years with mechanism-specific analyses
- Multivariable modeling and temporal trend assessment of device usage and outcomes
Limitations
- Observational design susceptible to residual confounding and selection bias
- Some subgroup estimates (e.g., acute ischemic MR) limited by small numbers and incomplete reporting in abstract
Future Directions: Mechanism-specific prospective studies and randomized comparisons within functional MR phenotypes; optimization of device strategy (number/position) and imaging guidance for efficiency and outcomes.
BACKGROUND: With the expansion of indications for mitral transcatheter edge-to-edge repair into nondegenerative etiologies, it is unknown whether changes in technical success and clinical outcomes have occurred. METHODS: The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/TVT) registry was analyzed from 2013 to 2023. Patients in shock were excluded. Patients were grouped by the mechanism of mitral regurgitation (MR) and divided into time periods. RESULTS: Overall, 68 028 patients were included. The application of mitral transcatheter edge-to-edge repair has evolved over the past decade to include more nondegenerative etiologies-increasing from 19% to 43%. The biggest growth was observed in functional MR (atrial and ventricular). Excluding acute ischemic MR, the odds of technical success were significantly higher for all mechanisms compared with degenerative MR (DMR). Over time more procedures were performed using only 1 implanted device (64.7% during 2022-2023 versus 54.6% during 2013-2017), without negatively impacting technical success. In multivariable analyses, the risk of 1-year heart failure readmission for ventricular functional MR was not higher than for DMR ( CONCLUSIONS: The application of mitral transcatheter edge-to-edge repair for nondegenerative etiologies increased considerably. While the odds of technical success were higher for all etiologies except acute ischemic MR, a similar 1-year mortality risk was observed in nondegenerative etiologies compared with DMR in real-world settings. These data support the use of mitral transcatheter edge-to-edge repair in degenerative and nondegenerative etiologies.